Management ChangeJul 6, 2026, 08:21 AM
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as CMO
AI Summary
Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Dr. Leonardo Viana Nicacio as Chief Medical Officer, effective August 3, 2026. His employment agreement includes an annual base salary of $545,000, eligibility for an annual bonus up to 40% of his base salary, and equity awards valued at $2,100,000. The company also provided updates on its clinical pipeline, expecting to initiate the CRB-701 registrational study in 2L OPSCC and report topline findings from the CRB-913 obesity study in late summer 2026.
Key Highlights
- Dr. Leonardo Viana Nicacio appointed Chief Medical Officer, effective August 3, 2026.
- Annual base salary for Dr. Nicacio set at $545,000.
- Eligible for an annual bonus targeted at up to 40% of his base salary.
- Granted equity awards with an aggregate grant date fair value of $2,100,000.
- CRB-701 registrational study (TEMPO-1) for 2L OPSCC expected to initiate in summer 2026.
- CRB-913 CANYON-1 obesity study topline results expected late summer 2026.
Price Impact
More from CRBP